138 related articles for article (PubMed ID: 34633954)
21. BRAF-Targeted Therapy in the Treatment of
Johanns TM; Ansstas G; Dahiya S
J Natl Compr Canc Netw; 2018 Apr; 16(4):451-454. PubMed ID: 29632063
[No Abstract] [Full Text] [Related]
22. Dabrafenib in BRAFV600E mutant pilocytic astrocytoma in a pediatric patient.
Mustansir F; Mushtaq N; Darbar A
Childs Nerv Syst; 2020 Jan; 36(1):203-207. PubMed ID: 31418082
[TBL] [Abstract][Full Text] [Related]
23. Dramatic clinical and radiographic response to BRAF inhibition in a patient with progressive disseminated optic pathway glioma refractory to MEK inhibition.
Bavle A; Jones J; Lin FY; Malphrus A; Adesina A; Su J
Pediatr Hematol Oncol; 2017 May; 34(4):254-259. PubMed ID: 29040023
[TBL] [Abstract][Full Text] [Related]
24. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.
Robinson GW; Orr BA; Gajjar A
BMC Cancer; 2014 Apr; 14():258. PubMed ID: 24725538
[TBL] [Abstract][Full Text] [Related]
25. Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor.
Grenier-Chartrand F; Barrit S; Racu ML; Luce S; Spitaels J; Sadeghi-Meibodi N; Lebrun L; Salmon I; Lefranc F; De Witte O
Acta Neurochir (Wien); 2022 Mar; 164(3):737-742. PubMed ID: 35029761
[TBL] [Abstract][Full Text] [Related]
26. Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report.
Piccolo G; Verrico A; Morana G; Piatelli G; De Marco P; Iurilli V; Antonelli M; Gaggero G; Ramaglia A; Crocco M; Caruggi S; Milanaccio C; Garrè ML; Pavanello M
BMC Pediatr; 2022 Nov; 22(1):685. PubMed ID: 36447197
[TBL] [Abstract][Full Text] [Related]
27. Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases.
Upadhyaya SA; Robinson GW; Harreld JH; Klimo PD; Hoehn ME; Orr BA; Qaddoumi IA
Childs Nerv Syst; 2018 Apr; 34(4):605-610. PubMed ID: 29392423
[TBL] [Abstract][Full Text] [Related]
28.
Del Bufalo F; Ceglie G; Cacchione A; Alessi I; Colafati GS; Carai A; Diomedi-Camassei F; De Billy E; Agolini E; Mastronuzzi A; Locatelli F
Front Oncol; 2018; 8():526. PubMed ID: 30488019
[TBL] [Abstract][Full Text] [Related]
29. Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib.
Grbčić P; Fučkar Čupić D; Gamberi T; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201061
[TBL] [Abstract][Full Text] [Related]
30. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
31. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas.
Lazow MA; Hoffman L; Schafer A; Osorio DS; Boué DR; Rush S; Wright E; Lane A; DeWire-Schottmiller MD; Smolarek T; Sipple J; Taggert H; Reuss J; Salloum R; Hummel TR; de Blank P; Pillay-Smiley N; Sutton ME; Asher A; Stevenson CB; Drissi R; Finlay JL; Fouladi M; Fuller C
Acta Neuropathol Commun; 2020 Nov; 8(1):182. PubMed ID: 33153497
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Role of BRAF Mutation in Low-Grade Gliomas: Meta-analysis.
Kai Z; Dingyang L; Zhuanyi Y
World Neurosurg; 2021 Mar; 147():42-46. PubMed ID: 33316486
[TBL] [Abstract][Full Text] [Related]
33. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.
Chamberlain MC
J Neurooncol; 2013 Sep; 114(2):237-40. PubMed ID: 23756728
[TBL] [Abstract][Full Text] [Related]
34. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.
Horbinski C; Nikiforova MN; Hagenkord JM; Hamilton RL; Pollack IF
Neuro Oncol; 2012 Jun; 14(6):777-89. PubMed ID: 22492957
[TBL] [Abstract][Full Text] [Related]
35. Dabrafenib Effective in Pediatric Glioma.
Cancer Discov; 2017 Jan; 7(1):OF5. PubMed ID: 28062673
[TBL] [Abstract][Full Text] [Related]
36. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
37. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Cheng L; Jin Y; Liu M; Ruan M; Chen L
Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
[TBL] [Abstract][Full Text] [Related]
38. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
[TBL] [Abstract][Full Text] [Related]
39. Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.
Burger MC; Ronellenfitsch MW; Lorenz NI; Wagner M; Voss M; Capper D; Tzaridis T; Herrlinger U; Steinbach JP; Stoffels G; Langen KJ; Brandts C; Senft C; Harter PN; Bähr O
Oncol Rep; 2017 Dec; 38(6):3291-3296. PubMed ID: 29039591
[TBL] [Abstract][Full Text] [Related]
40. Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment.
Tsai JW; Choi JJ; Ouaalam H; Murillo EA; Yeo KK; Vogelzang J; Sousa C; Woods JK; Ligon KL; Warfield SK; Bandopadhayay P; Cooney TM
Neurooncol Adv; 2023; 5(1):vdac182. PubMed ID: 36926246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
